Log In
Print this Print this

Imlygic, T-Vec, talimogene laherparepvec

Also known as: formerly OncoVEX GM-CSF

  Manage Alerts
Collapse Summary General Information
Company Amgen Inc.
DescriptionModified herpes simplex virus type 1 (HSV-1) carrying the gene for GM-CSF
Molecular Target Granulocyte macrophage colony-stimulating factor (GM-CSF) (CSF2)
Mechanism of ActionOncolytic virus
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentMarketed
Standard IndicationMelanoma
Indication DetailsLocal treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma that is recurrent after initial surgery; Treat advanced melanoma; Treat melanoma; Treat metastatic melanoma; Treat stage IIb-stage IV melanoma
Regulatory Designation U.S. - Orphan Drug (Treat stage IIb-stage IV melanoma);
U.S. - Special Protocol Assessment (Treat metastatic melanoma);
U.S. - Standard Review (Treat metastatic melanoma);
EU - Standard Review (Treat metastatic melanoma)

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today